Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR somatic variants status confers therapeutic sensitivity to Afatinib in patients with Non-Small Cell Lung Cancer.
Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).
This statement is based on a regulatory approval from the Health Canada:
GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).